What is Salignostics?
Salignostics is a leader in the development of accessible, rapid, and reliable saliva-based diagnostic solutions. Catering to healthcare providers, home-testing markets, and laboratories, the company's innovative platform overcomes the limitations of traditional diagnostics by offering non-invasive, cost-effective, and user-friendly testing. A key technological advancement is their unique saliva concentrator, which boosts biomarker detection and ensures consistent sample volumes for precise results. Salignostics has notably introduced Salistick, the first CE-approved saliva-based pregnancy test, marking a significant achievement in the diagnostics sector. The company's focus on enhancing diagnostic accuracy and patient convenience positions it for substantial growth in the healthcare technology landscape.
How much funding has Salignostics raised?
Salignostics has raised a total of $8M across 1 funding round:
Series A
$8M
Series A (2022): $8M with participation from Avigdor Orlinsky
What's next for Salignostics?
The recent major strategic investment provides Salignostics with substantial capital to further scale its operations and expand its innovative diagnostic offerings. This infusion of funding is expected to accelerate the development and commercialization of its saliva-based testing technologies, potentially broadening its market reach and solidifying its position as a key player in the diagnostics industry. The company's trajectory suggests a focus on enhancing biomarker detection capabilities and increasing the accessibility of its testing solutions, aligning with the growing demand for point-of-care and at-home diagnostic tools.
See full Salignostics company page
